Transmission-selective muscle pathology induced by the active propagation of mutant huntingtin across the human neuromuscular synapse

Front Mol Neurosci. 2024 Jan 3:16:1287510. doi: 10.3389/fnmol.2023.1287510. eCollection 2023.

Abstract

Neuron-to-neuron transmission of aggregation-prone, misfolded proteins may potentially explain the spatiotemporal accumulation of pathological lesions in the brains of patients with neurodegenerative protein-misfolding diseases (PMDs). However, little is known about protein transmission from the central nervous system to the periphery, or how this propagation contributes to PMD pathology. To deepen our understanding of these processes, we established two functional neuromuscular systems derived from human iPSCs. One was suitable for long-term high-throughput live-cell imaging and the other was adapted to a microfluidic system assuring that connectivity between motor neurons and muscle cells was restricted to the neuromuscular junction. We show that the Huntington's disease (HD)-associated mutant HTT exon 1 protein (mHTTEx1) is transmitted from neurons to muscle cells across the human neuromuscular junction. We found that transmission is an active and dynamic process that starts before aggregate formation and is regulated by synaptic activity. We further found that transmitted mHTTEx1 causes HD-relevant pathology at both molecular and functional levels in human muscle cells, even in the presence of the ubiquitous expression of mHTTEx1. In conclusion, we have uncovered a causal link between mHTTEx1 synaptic transmission and HD pathology, highlighting the therapeutic potential of blocking toxic protein transmission in PMDs.

Keywords: Huntington's disease; hiPSC; mutant huntingtin; neurodegeneration; neuromuscular system; protein transmission; synaptic.

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by a Swiss National Science Foundation professorship grant (PP00P3_163937; PP00P3_194806) and a Synapsis foundation—Alzheimer's Research Switzerland ARS grant for principal investigators to EP-V.